Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Evolving Role for Pharmacotherapy in NAFLD/NASH
Suzanna Attia, Samir Softic, Marialena Mouzaki
Clinical and Translational Science (2020) Vol. 14, Iss. 1, pp. 11-19
Open Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Dean G. Brown, Heike J. Wobst
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 5, pp. 2312-2338
Closed Access | Times Cited: 217
Global prevalence of nonalcoholic fatty liver disease: an updated meta-analysis on 78 million population over 38 countries
Ehsan Amini‐Salehi, Negin Letafatkar, Naeim Norouzi, et al.
Archives of Medical Research (2024) Vol. 55, Iss. 6, pp. 103043-103043
Closed Access | Times Cited: 35
Perspectives in liver redox imbalance: Toxicological and pharmacological aspects underlying iron overloading, nonalcoholic fatty liver disease, and thyroid hormone action
Luis A. Videla, Rodrigo Valenzuela
BioFactors (2021) Vol. 48, Iss. 2, pp. 400-415
Closed Access | Times Cited: 62
Exercise of high intensity ameliorates hepatic inflammation and the progression of NASH
Gavin Fredrickson, Fanta Barrow, Katrina Dietsche, et al.
Molecular Metabolism (2021) Vol. 53, pp. 101270-101270
Open Access | Times Cited: 56
SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
Jun Sung Moon, Jun Hwa Hong, Yong Jin Jung, et al.
Trends in Endocrinology and Metabolism (2022) Vol. 33, Iss. 6, pp. 424-442
Closed Access | Times Cited: 46
Fibroblast Growth Factor–Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications
Leigang Jin, Ranyao Yang, Leiluo Geng, et al.
The Annual Review of Pharmacology and Toxicology (2022) Vol. 63, Iss. 1, pp. 359-382
Open Access | Times Cited: 43
Fructose impairs fat oxidation: Implications for the mechanism of western diet-induced NAFLD
Mustafa Kutlu Inci, Sehyung Park, Robert N. Helsley, et al.
The Journal of Nutritional Biochemistry (2022) Vol. 114, pp. 109224-109224
Open Access | Times Cited: 40
Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future
João Paulo Margiotti dos Santos, Mariana Canevari de Maio, Monike Alves Lemes, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 1, pp. 498-498
Open Access | Times Cited: 38
The role of FGF21 and its analogs on liver associated diseases
Kimia Falamarzi, Mahdi Malekpour, Mobin Fallah Tafti, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 38
Thyroid Hormone Receptor-β Agonists in NAFLD Therapy: Possibilities and Challenges
Limei Li, Yan Song, Yongquan Shi, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 108, Iss. 7, pp. 1602-1613
Closed Access | Times Cited: 23
Different Dietary Approaches, Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease: A Literature Review
José D. Torres‐Peña, Antonio P. Arenas-de Larriva, Juan F. Alcalá‐Díaz, et al.
Nutrients (2023) Vol. 15, Iss. 6, pp. 1483-1483
Open Access | Times Cited: 23
Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression
J. Jaeger, Annette Brandt, Wenfang Gui, et al.
JHEP Reports (2024) Vol. 6, Iss. 3, pp. 100987-100987
Open Access | Times Cited: 11
Mechanisms underpinning the effect of exercise on the non-alcoholic fatty liver disease: review.
Mohamed Bekheit, B S Kamera, Laura Colacino, et al.
PubMed (2025) Vol. 24, pp. 238-266
Closed Access | Times Cited: 1
Tissue-Specific Fructose Metabolism in Obesity and Diabetes
Robert N. Helsley, F. Moreau, Manoj K. Gupta, et al.
Current Diabetes Reports (2020) Vol. 20, Iss. 11
Open Access | Times Cited: 51
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
V. A. Prikhodko, Natalia N. Bezborodkina, Sergey V. Okovityi
Biomedicines (2022) Vol. 10, Iss. 2, pp. 274-274
Open Access | Times Cited: 37
Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
Eva K. Wirth, Tobias Puengel, Joachim Spranger, et al.
Expert Review of Endocrinology & Metabolism (2022) Vol. 17, Iss. 5, pp. 425-434
Closed Access | Times Cited: 34
Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis
Qingfu Zhu, Hengrui Li, Zheng Ao, et al.
Journal of Nanobiotechnology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 32
Adipokines as Clinically Relevant Therapeutic Targets in Obesity
Marleen Würfel, Matthias Blüher, Michael Stümvoll, et al.
Biomedicines (2023) Vol. 11, Iss. 5, pp. 1427-1427
Open Access | Times Cited: 22
Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges
Haoyu Tian, Shuairan Zhang, Ying Liu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4583-4583
Open Access | Times Cited: 21
Fgf21-Dubosiella axis mediates the protective effects of exercise against NAFLD development
Xiaochun Ye, Peng Sun, Shuaiwei Lao, et al.
Life Sciences (2023) Vol. 334, pp. 122231-122231
Closed Access | Times Cited: 20
Metabolic Role of Autophagy in the Pathogenesis and Development of NAFLD
Lingxuan An, Ulrich Wirth, Dominik Koch, et al.
Metabolites (2023) Vol. 13, Iss. 1, pp. 101-101
Open Access | Times Cited: 19
Fructose induced KHK-C can increase ER stress independent of its effect on lipogenesis to drive liver disease in diet-induced and genetic models of NAFLD
Sehyung Park, Robert N. Helsley, Taghreed Fadhul, et al.
Metabolism (2023) Vol. 145, pp. 155591-155591
Open Access | Times Cited: 19
The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus
Monika Bhardwaj, Papiya Mitra Mazumder
Naunyn-Schmiedeberg s Archives of Pharmacology (2024)
Closed Access | Times Cited: 7
Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials
Mohamed Mahmoud Marey, Mohamed Mohamed Belal, Abdelaziz A. Awad, et al.
Clinics and Research in Hepatology and Gastroenterology (2024) Vol. 48, Iss. 6, pp. 102357-102357
Open Access | Times Cited: 6
Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk
Siarhei A. Dabravolski, Evgeny E. Bezsonov, Mirza S. Baig, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4459-4459
Open Access | Times Cited: 38
Page 1 - Next Page

Scroll to top